The US Food and Drug Administration (FDA) has accepted an expanded peripheral artery illness (PAD) indication for the negate oral anticoagulant rivaroxaban (Xarelto) to consist…
The US Food and Drug Administration (FDA) has accepted an expanded peripheral artery illness (PAD) indication for the negate oral anticoagulant rivaroxaban (Xarelto) to consist…